JOAO ALBERTO OSSO JUNIOR

JOAO ALBERTO OSSO JUNIOR

(Fonte: Lattes)

ORCID

ScopusID

Resumo

Possui graduação em Química pela Universidade de São Paulo (1978), mestrado em Engenharia Nuclear pela Universidade Federal do Rio de Janeiro (1982) e doutorado em Ph D em Química Nuclear - University of Manchester (1986). Atualmente é pesquisador da Comissão Nacional de Energia Nuclear, revisor dos journals - Brazilian Archives of Biology and Technology, - Applied Radiation and Isotopes e professor pós-graduação da Universidade de São Paulo. Tem experiência na área de Engenharia Nuclear, com ênfase em Produção de Radioisótopos, atuando principalmente nos seguintes temas: medicina nuclear, tecnecio-99m, gerador tipo gel, reator nuclear e ciclotron. (Texto extraído do Currículo Lattes em 8 maio 2023)

Página do item completo

Resultados de Busca

Agora exibindo 1 - 1 de 1

Pharmacokinetic of meglumine antimoniate encapsulated in phosphatidylserine-liposomes in mice model
2018 - BORBOREMA, SAMANTA E.T.; OSSO JUNIOR, JOAO A.; TEMPONE, ANDRE G.; ANDRADE JUNIOR, HEITOR F. de; NASCIMENTO, NANCI do
Visceral leishmaniasis (VL) is a fatal parasitic disease caused by the protozoan Leishmania spp. Meglumine antimoniate (MA) is the main treatment and has demonstrated a promising efficacy in a VL-model when encapsulated into negatively charged liposomes. Considering the current concept for the evaluation of pharmacokinetic parameters at early phases of drug discovery, we developed a formulation of MA-encapsulated into phosphatidylserine liposomes (MA-LP) and analyzed the in vitro antileishmanial activity, physicochemical properties, and pharmacokinetic profile in a mice model. The liposomal formulation had an internal mean diameter of 114 nm and a high stability in plasma. MA-LP was 23-fold more in vitro effective against Leishmania infantum-infected macrophages than the free drug, with a selectivity index higher than 220. The pharmacokinetic studies demonstrated that the liposomes increased the uptake of the drug by the liver and spleen and promoted sustained levels. MA-LP was first eliminated through renal excretion, followed by biliary excretion. In the blood, MA-LP followed a biexponential open model. This work emphasizes the importance of liposomes as potential drug delivery systems for visceral leishmaniasis.